Skip to main content
40214 Suchergebnisse für:

Hepatitis E 

sortieren nach |
"Aktualität" sortiert die Ergebnisse nach Publikationsdatum. "Relevanz" berücksichtigt auch noch andere Faktoren wie zum Beispiel die Häufigkeit der Suchbegriffe im Text.
  1. 13.03.2024 | Hepatitis C | ReviewPaper

    Stand der nationalen und globalen Hepatitis-C-Elimination

    Die Therapie der chronischen Hepatitis-C-Virus(HCV)-Infektion hat sich in den letzten Jahren dramatisch gewandelt. Bereits 2016 hat die WHO die Elimination des HCV bis zum Jahr 2030 propagiert. Dieser Beitrag beschäftigt sich mit den Fortschritten, die global sowie in Deutschland seither zu verzeichnen sind.

  2. 16.02.2024 | Hepatitis B | ReviewPaper
    Hepatologie - Teil 1 Hepatitis

    Hepatitis-B- und -C-Screening im Rahmen des Check-up 35 - eine Erfolgsgeschichte?

    Um unerkannte oder auch neu Erkrankte mit einer chronischen Hepatitis B und C möglichst zeitnah zu erkennen, wurde ab dem 1. Oktober 2021 ein einmaliges Screening auf Hepatitis B und C in die Gesundheitsuntersuchung ab 35 Jahren für GKV-Versicherte durch den Gemeinsamen Bundesausschuss aufgenommen. Zur aktuellen Entwicklungen der Hepatitis-B und -C-Neudiagnosen und der antiviralen Behandlungen der Hepatitis C in Deutschland sowie dem Effekt des Screeningprogramms liegen jetzt Daten bis zum 31. Dezember 2023 vor.

  3. Open Access 21.02.2024 | ReviewPaper

    Hepatitis B Virus Elimination Strategies

    Globally, hepatitis B virus (HBV) is a major health problem, with an estimated 257.5 million people infected (3.23% of the population in 2022) and 820,000 deaths in 2019 [ 1 •, 2 ]. Progress in global vaccine distribution and improved antiviral …

  4. 08.03.2024 | Online First

    A comparative study of uncomplicated acute non-A-E hepatitis with acute viral hepatitis and acute onset autoimmune hepatitis

    Non-A-E hepatitis (NAEH) is a well-recognized cause for acute liver failure (ALF). It is also known as indeterminate, cryptogenic, seronegative, non-A non-B, non-A non-B non-C and non-A non-E hepatitis [ 1 ]. It is a common indication for liver …

  5. Open Access 01.12.2024 | OriginalPaper

    Hepatitis B virus infection among illegal drug users in Enugu State, Nigeria: prevalence, immune status, and related risk factors

    Hepatitis B virus infection is a global health challenge that jeopardizes public health and security. An estimated 296 million people worldwide are living with chronic HBV infection, and each year 1.5 million new infections and 1.2 million …

  6. 01.07.2024 | Letter

    Evaluation of risk for hepatitis B virus reactivation in patients with psoriasis treated with biologic therapies: a single-center retrospective study

  7. 23.04.2024 | Online First

    Hepatic and Extrahepatic Characteristics of Autoimmune Hepatitis: A 23-year Hospital-Based Cohort Study

    Autoimmune hepatitis (AIH) is a necroinflammatory liver disease that occurs in patients of all ages [ 1 ]. AIH is a prototypical autoimmune disease with a female predominance. The etiology of AIH remains mostly unresolved but likely results from …

  8. 01.05.2024 | BriefCommunication

    Development of an effective single-chain variable fragment recognizing a novel epitope in the hepatitis C virus E2 protein that restricts virus entry into hepatocytes

    Previously, we reported a neutralizing monoclonal antibody, A8A11, raised against a novel conserved epitope within the hepatitis C virus (HCV) E2 protein, that could significantly reduce HCV replication. Here, we report the nucleotide sequence of …

  9. Open Access 10.02.2024 | ReviewPaper

    Perspective on Emerging Therapies to Achieve Functional Cure of Chronic Hepatitis B

    Despite the availability of a safe and effective vaccine for over four decades, the global health burden of hepatitis B virus (HBV) infection remains high. Recent estimates suggest there are ~ 300 million people with chronic infection resulting in …

  10. Open Access 01.12.2024 | OriginalPaper

    Hepatitis C screening in Lithuania: first-year results and scenarios for achieving WHO elimination targets

    Viral hepatitis C (HCV) infections are a significant global public health challenge, affecting approximately 1% of the world’s population [ 1 ]. Currently, there is no vaccine to prevent the transmission of HCV. An estimated 5 million Europeans are …

  11. Open Access 01.12.2024 | OriginalPaper

    Survey of lived experiences and challenges in hepatitis B management and treatment

    Almost 300 million people are living with chronic hepatitis B infection worldwide and most remain undiagnosed and at risk for liver cancer. In 2015 the World Health Organization (WHO) developed guidelines for the prevention, care, and treatment of …

  12. Open Access 01.12.2024 | OriginalPaper

    Hepatitis B relapse after entecavir or tenofovir alafenamide cessation under anti-viral prophylaxis for cancer chemotherapy

    Because the covalently closed circular DNA of HBV serves as a template for viral replication, patients with both cancer and HBV are at risk of HBV reactivation (HBVr) when they undergo cytotoxic or immunosuppressive therapy, and this risk is …

  13. Open Access 01.12.2024 | OriginalPaper

    Patients’ experience of accessing hepatitis C treatment through the Myanmar national hepatitis C treatment program: a qualitative evaluation

    Globally, approximately 56.8 million people are living with hepatitis C and over three-quarters of those reside in low and middle-income countries (LMICs) [ 1 ]. Since the introduction of direct-acting antiviral (DAA) treatments for hepatitis C

  14. 13.04.2024 | Online First

    Succinic Acid Ameliorates Concanavalin A-Induced Hepatitis by Altering the Inflammatory Microenvironment and Expression of BCL-2 Family Proteins

    Autoimmune hepatitis (AIH) is a severe immune-mediated inflammatory liver disease that currently lacks feasible drug treatment methods. Our study aimed to evaluate the protective effect of succinic acid against AIH and provide a reliable method …

  15. Open Access 01.12.2024 | OriginalPaper

    Collateral effects of COVID-19 countermeasures on hepatitis E incidence pattern: a case study of china based on time series models

    Hepatitis E is a major public health problem and one of the most frequent causes of acute hepatitis worldwide. The global burden of hepatitis E is high; every year, there are approximately 20 million hepatitis E virus (HEV) infections, leading to …

  16. Open Access 01.12.2024 | OriginalPaper

    Viscoelastic parameters derived from multifrequency MR elastography for depicting hepatic fibrosis and inflammation in chronic viral hepatitis

    Chronic liver diseases caused by viral hepatitis infections represent a significant global health concern [ 1 , 2 ]. Fibrosis, a well-documented consequence of these diseases, is a dynamic process that can be reversed with appropriate treatment …

  17. Open Access 05.04.2024 | Online First

    Seroprevalence and Shifting Endemicities of Hepatitis A Virus Infection in Two Different Geographical Areas in the Philippines

    Hepatitis A is an infectious disease caused by the hepatitis A virus (HAV), which is an RNA virus belonging to the picornavirus family, and infects primarily humans as its only natural host [ 1 ]. HAV is transmitted primarily by the fecal-oral …

  18. 20.02.2024 | OriginalPaper

    Effect of Concurrent Metabolic Dysfunction-Associated Steatotic Liver Disease on Serial Non-invasive Fibrosis Markers in Chronic Hepatitis B

    Chronic hepatitis B (CHB) is a persistent liver infection with the hepatitis B virus (HBV) that affects approximately 250 million people globally [ 1 ]. CHB-related morbidity and mortality are due to the development of liver failure from cirrhosis …

  19. Open Access 01.12.2024 | OriginalPaper

    The effect of intrahepatic cholestasis in pregnancy combined with different stages of hepatitis B virus infection on pregnancy outcomes: a retrospective study

    Intrahepatic cholestasis during pregnancy (ICP) is a common complication of pregnancy, characterized by elevated bile acid levels, skin pruritus, and elevated transaminase levels in the second half of pregnancy. ICP can lead to complications such …

  20. Open Access 01.12.2024 | OriginalPaper

    Evaluating hepatitis C cascade of care surveillance system in Tuscany, Italy, through a population retrospective data-linkage study, 2015–2021

    This comprehensive retrospective data-linkage study aimed at evaluating the impact of Direct-Acting Antivirals (DAAs) on Hepatitis C Virus (HCV) testing, treatment trends, and access to care in Tuscany over six years following their introduction.

Suchergebnisse filtern:

e.Medpedia

Hepatitis E-Virus (HEV)

Lexikon der Medizinischen Laboratoriumsdiagnostik
Hepatitis E-Virus (HEV)

weitere e.Medpedia Einträge

Suchoperatoren:

„ ... ... “ Findet Dokumente mit genau dieser Wortgruppe in exakt dieser Schreibweise und Reihenfolge (z.B., "rheumatische Beschwerden").
AND / UND Findet Dokumente, in denen beide Begriffe zusammen vorkommen (z.B., alkohol UND demenz).
OR / ODER Findet Dokumente, in denen einer der beiden oder beide Begriffe vorkommen (z.B., hiv ODER aids).
Leerzeichen Findet Dokumente, in denen alle Begriffe vorkommen. Der Leerschritt wird als UND interpretiert (z.B., isolierte systolische hypertonie).
NOT / NICHT Findet Dokumente, in denen der Begriff nach NOT nicht vorkommt (z.B., sars NOT sars-cov-2).
COUNT(...)>n Findet Dokumente, in denen der gesuchte Begriff mehr als n mal vorkommt. n steht für eine beliebige Anzahl (z.B., COUNT(mammakarzinom)>8).
NEAR(..., ..., ) Findet Dokumente, in denen beide Begriffe in beliebiger Reihenfolge innerhalb von maximal n Worten zueinander stehen. Empfehlung: wählen Sie zwischen 15 und 30 als maximale Wortanzahl (z.B., NEAR(covid, diabetes,20)).
* Findet Dokumente, in denen der Begriff in Wortvarianten vorkommt, wobei diese VOR, HINTER oder VOR und HINTER dem Suchbegriff anschließen können (z.B., thrombose*, *thrombose, *thrombose*).
? Findet Dokumente mit dem Suchbegriff in verschiedenen Schreibweisen, hier mit s oder z, also organisation und organization. Das ? steht für eine einzige Stelle (z.B., organi?ation).
& + - Sonderzeichen werden als UND interpretiert (z.B., Diagnose + Therapie).

Sie können Operatoren mit Ihrer Suchanfrage kombinieren, um diese noch präziser einzugrenzen.

Fahren Sie mit der Maus über den Suchoperator, um eine Erklärung seiner Funktionsweise anzuzeigen.